Patents by Inventor Aude Garcel

Aude Garcel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10806729
    Abstract: The present invention relates to a quinoline derivative of formula (I) or anyone of its pharmaceutically acceptable salt, or anyone of its metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient; and then terminating said treatment when: the viral load is low or undetectable; and/or the level of CD4+ cell count is maintained or restored.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: October 20, 2020
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Didier Scherrer, Aude Garcel, Noelie Campos, Jamal Tazi, Audrey Vautrin, Florence Mahuteau, Romain Najman, Pauline Fornarelli
  • Patent number: 10718770
    Abstract: The present invention relates to a method for screening a compound useful for treating or preventing a viral infection or a virus-related condition in an individual, comprising at least the steps of: a) determining the ability of a candidate compound to promote the interaction between CBP20 and CBP80 in a sample, and b) selecting the candidate compound that is determined to promote said interaction at step a). The present invention further relates to a method for screening a compound useful for treating or preventing a viral infection or virus-related condition in an individual, comprising at least the steps of: a) determining the ability of a candidate compound to interact with CBP20 or CBP80 in a sample, and b) selecting the candidate compound that is determined to interact with CBP20 or CBP80 at step a).
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: July 21, 2020
    Assignees: ABIV AX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Didier Scherrer, Aude Garcel, Noelie Campos, Jamal Tazi, Audrey Vautrin, Florence Mahuteau, Romain Najman, Pauline Fornarelli
  • Patent number: 10329317
    Abstract: The present invention relates to a quinoline derivative of formula (1) or one of its pharmaceutically acceptable salts. The present invention further relates to said quinoline derivative for medicament and for use in the treatment or prevention of a viral or retroviral infection and in particular AIDS or an AIDS-related condition or Human Immunodeficiency virus (HIV). The present invention also relates to a pharmaceutical composition comprising said quinoline derivative and to the process for preparing it as to a novel intermediate compound.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: June 25, 2019
    Assignees: ABIV AX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Didier Scherrer, Aude Garcel, Noelie Campos, Jamal Tazi, Audrey Vautrin, Florence Mahuteau, Romain Najman, Pauline Fornarelli
  • Patent number: 10253020
    Abstract: The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R? is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: April 9, 2019
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal Tazi, Florence Mahuteau, Pierre Roux, Romain Najman, Didier Scherrer, Carsten Brock, Nathalie Cahuzac, Gilles Gadea, Noelie Campos, Aude Garcel, Julien Santo
  • Patent number: 10017498
    Abstract: A compound having the following formula or a pharmaceutically acceptable salt thereof: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NR1R2 group, a (C1-C3)fluoroalkoxy group, a —NO2 group, a phenoxy group, or a (C1-C4)alkoxy group, R1 and R2 are independently a hydrogen atom or a (C1-C3)alkyl group, R? is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, or a (C1-C4)alkoxy group, R? is a hydrogen atom or a (C1-C4)alkyl group, n is 1, 2, or 3, and n? is 1 or 2.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: July 10, 2018
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal Tazi, Florence Mahuteau, Romain Najman, Didier Scherrer, Noelie Campos, Aude Garcel
  • Patent number: 9908869
    Abstract: A compound having the following formula or a pharmaceutically acceptable salt thereof: where: R? is a hydrogen atom or a (C1-C4)alkyl group; n? is 1 or 2; n is 1, 2, or 3; R independently represents a hydrogen atom, a halogen atom, or a group selected from a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —NR1R2 group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a (C1-C3)fluoroalkoxy, and a (C1-C4)alkoxy group; R? is a hydrogen atom, a halogen atom, or a group selected from a (C1-C3)alkyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a (C1-C4)alkoxy group, and a CN group; R1 and R2 are a hydrogen atom or a (C1-C3)alkyl group; with the proviso that when R and R? are not simultaneously a hydrogen atom: when n is 1, R is not a methyl group in an ortho or para position with respect to N, when R? is a hydrogen atom, R is not a bromine atom or a chlorine atom, and when R is a hydrogen atom, R? is not a methyl or ethyl group, a —COOH group, a —COOC2H5 group, or a bromine atom that
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: March 6, 2018
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal Tazi, Florence Mahuteau, Romain Najman, Didier Scherrer, Noelie Campos, Aude Garcel
  • Publication number: 20180030078
    Abstract: The present invention relates to a quinoline derivative of formula (1) or one of its pharmaceutically acceptable salts. The present invention further relates to said quinoline derivative for medicament and for use in the treatment or prevention of a viral or retroviral infection and in particular AIDS or an AIDS-related condition or Human Immunodeficiency virus (HIV). The present invention also relates to a pharmaceutical composition comprising said quinoline derivative and to the process for preparing it as to a novel intermediate compound.
    Type: Application
    Filed: February 19, 2016
    Publication date: February 1, 2018
    Inventors: Didier SCHERRER, Aude GARCEL, Noelie CAMPOS, Jamal TAZI, Audrey VAUTRIN, Florence MAHUTEAU, Romain NAJMAN, Pauline FORNARELLI
  • Publication number: 20180028522
    Abstract: The present invention relates to a quinoline derivative of formula (I) or anyone of its pharmaceutically acceptable salt, or anyone of its metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient; and then terminating said treatment when: the viral load is low or undetectable; and/or the level of CD4+ cell count is maintained or restored.
    Type: Application
    Filed: February 19, 2016
    Publication date: February 1, 2018
    Inventors: Didier SCHERRER, Aude GARCEL, Noelie CAMPOS, Jamal TAZI, Audrey VAUTRIN, Florence MAHUTEAU, Romain NAJMAN, Pauline FORNARELLI
  • Publication number: 20180031557
    Abstract: The present invention relates to a method for screening a compound useful for treating or preventing a viral infection or a virus-related condition in an individual, comprising at least the steps of: a) determining the ability of a candidate compound to promote the interaction between CBP20 and CBP80 in a sample, and b) selecting the candidate compound that is determined to promote said interaction at step a). The present invention further relates to a method for screening a compound useful for treating or preventing a viral infection or virus-related condition in an individual, comprising at least the steps of: a) determining the ability of a candidate compound to interact with CBP20 or CBP80 in a sample, and b) selecting the candidate compound that is determined to interact with CBP20 or CBP80 at step a).
    Type: Application
    Filed: February 19, 2016
    Publication date: February 1, 2018
    Inventors: Didier SCHERRER, Aude GARCEL, Noelie CAMPOS, Jamal TAZI, Audrey VAUTRIN, Florence MAHUTEAU, Romain NAJMAN, Pauline FORNARELLI
  • Patent number: 9827237
    Abstract: Methods for preventing or treating retroviral infection not HIV and/or for preventing, inhibiting or treating a disease caused by the retroviral infection include contacting a cell with compound (I) wherein: means a pyridazine, pyrimidine or pyrazine group, R independently represent a hydrogen atom, halogen atom or group chosen among a —CN, hydroxyl, —COOR1, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, —NO2, —NR1R2, (C1-C4)alkoxy, phenoxy and (C1-C3)alkyl group, the alkyl being optionally mono-substituted by hydroxyl group, n is 1, 2 or 3, n? is 1 or 2, R? is a hydrogen atom, halogen atom or group chosen among (C1-C3)alkyl group, hydroxyl group, —COOR1 group, —NO2 group, —NR1R2 group, morpholinyl or morpholino group, N-methylpiperazinyl group, (C1-C3)fluoroalkyl group, (C1-C4)alkoxy group and —CN group, Z is N or C, Y is N or C, X is N or C, W is N or C, T is N or C, U is N or C.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: November 28, 2017
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIE
    Inventors: Jamal Tazi, Florence Mahuteau-Betzer, Romain Najman, Didier Scherrer, Noëlie Campos, Aude Garcel
  • Publication number: 20170226095
    Abstract: The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R? is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.
    Type: Application
    Filed: April 13, 2017
    Publication date: August 10, 2017
    Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal TAZI, Florence MAHUTEAU, Pierre ROUX, Romain NAJMAN, Didier SCHERRER, Carsten BROCK, Nathalie CAHUZAC, Gilles GADEA, Noelie CAMPOS, Aude GARCEL, Julien SANTO
  • Publication number: 20170197938
    Abstract: The present invention relates to a compound of formula (1) in the form of a base or addition salt with an acid, particularly a pharmaceutically acceptable acid. It further relates to a pharmaceutical composition including the compound and at least one pharmaceutically acceptable excipient, to a process for preparing said compound and to a corresponding intermediate compound.
    Type: Application
    Filed: July 17, 2015
    Publication date: July 13, 2017
    Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal TAZI, Romain NAJMAN, Florence MAHUTEAU, Didier SCHERRER, Aude GARCEL, Noëlie CAMPOS
  • Patent number: 9556489
    Abstract: The present invention relates to the use (i) of a level of expression of a long RBM39 protein isoform, termed RBM39L, and (ii) of a level of expression of a short RBM39 protein isoform, termed RBM39C, as a marker for the efficacy of an active agent capable of preventing and/or treating HIV infection.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: January 31, 2017
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), UNIVERSITE DE MONTPELLIER, INSTITUT CURIE
    Inventors: Jamal Tazi, Julian Venables, Aude Garcel, Noëlle Campos, Florence Mahuteau-Betzer, Romain Najman, Didier Scherrer
  • Publication number: 20160151348
    Abstract: Methods for preventing or treating retroviral infection not HIV and/or for preventing, inhibiting or treating a disease caused by the retroviral infection include contacting a cell with compound (I) wherein: means a pyridazine, pyrimidine or pyrazine group, R independently represent a hydrogen atom, halogen atom or group chosen among a —CN, hydroxyl, —COOR1, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, —NO2, —NR1R2, (C1-C4)alkoxy, phenoxy and (C1-C3)alkyl group, the alkyl being optionally mono-substituted by hydroxyl group, n is 1, 2 or 3, n? is 1 or 2, R? is a hydrogen atom, halogen atom or group chosen among (C1-C3)alkyl group, hydroxyl group, —COOR1 group, —NO2 group, —NR1R2 group, morpholinyl or morpholino group, N-methylpiperazinyl group, (C1-C3)fluoroalkyl group, (C1-C4)alkoxy group and —CN group, Z is N or C, Y is N or C, X is N or C, W is N or C, T is N or C, U is N or C.
    Type: Application
    Filed: July 4, 2014
    Publication date: June 2, 2016
    Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal TAZI, Florence MAHUTEAU-BETZER, Romain NAJMAN, Didier SCHERRER, Noëlie CAMPOS, Aude GARCEL
  • Publication number: 20150361491
    Abstract: A use of at least one miRNA, said at least one miRNA being miR-124, as a biomarker, in particular of a viral infection, or of an efficacy of a therapeutic treatment of said viral infection.
    Type: Application
    Filed: January 17, 2014
    Publication date: December 17, 2015
    Inventors: Jamal TAZI, Didier SCHERRER, Aude GARCEL, Noëlie CAMPOS, Romain NAJMAN, Florence MAHUTEAU-BETZER
  • Publication number: 20150307478
    Abstract: A compound having the following formula or a pharmaceutically acceptable salt thereof: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NR1R2 group, a (C1-C3)fluoroalkoxy group, a —NO2 group, a phenoxy group, or a (C1-C4)alkoxy group, R1 and R2 are independently a hydrogen atom or a (C1-C3)alkyl group, R? is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, or a (C1-C4)alkoxy group, R? is a hydrogen atom or a (C1-C4)alkyl group, n is 1, 2, or 3, and n? is 1 or 2.
    Type: Application
    Filed: July 1, 2015
    Publication date: October 29, 2015
    Inventors: Jamal TAZI, Florence MAHUTEAU, Romain NAJMAN, Didier SCHERRER, Noelie CAMPOS, Aude GARCEL
  • Patent number: 9145367
    Abstract: The present invention relates to compound Formula (I) wherein: Formula (II) means a pyridazine, a pyrimidine or a pyrazine group, R independently represent a hydrogen atom, a halogen atom or a group chosen among a CN group, a hydroxyl group, a COOR1 group, a (C1-C3)fluoroalkyl group, a (C1-C3)fluoroalkoxy group, a NO2 group, a NR1R2 group, a (C1-C4)alkoxy group, a phenoxy group and a (C1-C3)alkyl group, said alkyl being optionally mono-substituted by a hydroxyl group, n is 1, 2 or 3, n is 1 or 2, R is a hydrogen atom, a halogen atom or a group chosen among a (C1-C3)alkyl group, a hydroxyl group, a COOR1 group, a NO2 group, a NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a (C1-C4)alkoxy group and a CN group, Z is N or C, Y is N or C, X is N or C, W is N or C, T is N or C, U is N or C, for use as an agent for preventing, inhibiting or treating AIDS. Some of said compounds are new and also form part of the invention.
    Type: Grant
    Filed: June 14, 2010
    Date of Patent: September 29, 2015
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER 2
    Inventors: Jamal Tazi, Florence Mahuteau, Romain Najman, Didier Scherrer, Noelie Campos, Aude Garcel
  • Patent number: 9061999
    Abstract: The present invention relates to compound (I) for use as an agent for preventing, inhibiting or treating AIDS, wherein X is CR0 or N; R0, R1, R2, R3, R4, R7 and R8 independently represent a hydrogen atom, a halogen atom or a group chosen among a (C1-C5)alkyl group, a (C3-C6)cycloalkyl group, a (C1-C5)fluoroalkyl group, a (C1-C5)alkoxy group, a (C1-C5)fluoroalkoxy group, a —CN group, a —COORa group, a —NO2 group, a —NRaRb group, a —NRa—SO2—NRaRb group, a —NRa—SO2—Ra group, a —NRa—C(?O)—Ra group, a —NRa—C(?O)—NRaRb group, a —SO2—NRaRb group, a —SO3H group, a —OH group, a —O—SO2—ORc group, a —O—P(?O)—(ORc)(ORd) group, a —O—CH2—COORc group and can further be a group chosen among: R5 represents a hydrogen atom, a (C1-C5)alkyl group or a (C3-C6)cycloalkyl group; R10 is a hydrogen atom or a chlorine atom, and R11 is a hydrogen atom or a (C1-C4)alkyl group or anyone of its pharmaceutically acceptable salts.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: June 23, 2015
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE MONTPELLIER 2
    Inventors: Jamal Tazi, Florence Mahuteau, Romain Najman, Didier Scherrer, Noëlie Campos, Aude Garcel
  • Publication number: 20150072892
    Abstract: The present invention relates to the use (i) of a level of expression of a long RBM39 protein isoform, termed RBM39L, and (ii) of a level of expression of a short RBM39 protein isoform, termed RBM39C, as a marker for the efficacy of an active agent capable of preventing and/or treating HIV infection.
    Type: Application
    Filed: March 4, 2013
    Publication date: March 12, 2015
    Inventors: Jamal Tazi, Julian Venables, Aude Garcel, Noëlle Campos, Florence Mahuteau-Betzer, Romain Najman, Didier Scherrer
  • Publication number: 20140288120
    Abstract: A compound having the following formula or a pharmaceutically acceptable salt thereof: where: R? is a hydrogen atom or a (C1-C4)alkyl group; n? is 1 or 2; n is 1, 2, or 3; R independently represents a hydrogen atom, a halogen atom, or a group selected from a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —NR1R2 group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a (C1-C3)fluoroalkoxy, and a (C1-C4)alkoxy group; R? is a hydrogen atom, a halogen atom, or a group selected from a (C1-C3)alkyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a (C1-C4)alkoxy group, and a CN group; R1 and R2 are a hydrogen atom or a (C1-C3)alkyl group; with the proviso that when R and R? are not simultaneously a hydrogen atom: when n is 1, R is not a methyl group in an ortho or para position with respect to N, when R? is a hydrogen atom, R is not a bromine atom or a chlorine atom, and when R is a hydrogen atom, R is not a methyl or ethyl group, a —COOH group, a —COOC2H5 group, or a bromine atom that is
    Type: Application
    Filed: April 18, 2014
    Publication date: September 25, 2014
    Applicants: SOCIETE SPLICOS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE MONTPELLIER 2
    Inventors: Jamal TAZI, Florence MAHUTEAU, Romain NAJMAN, Didier SCHERRER, Noelie CAMPOS, Aude GARCEL